Clinical experience with the use of Neoadjuvant hormone therapy for Breast Cancer in a Latin American cancer center
Ver / Descargar
Fecha
2020-05-25Autor(es)
Díaz, SandraSerrano, Wilmar
Sánchez, Ricardo
Orozco, Martha Cecilia
Mendoza, Sara
Nuñez-Lemus, Marcela
García, Mauricio
Lehmann, Carlos
Angel, Javier
Duarte, Carlos
Guzman, Luis
Cervera, Sergio
Osorio, Ana María
Autor(es) Corporativo(s)
Pontificia Universidad Javeriana. Facultad de Medicina. Departamento de Cirugía y Especialidades. Grupo de Investigación de Cirugía y Especialidades
Tipo
Artículo de revista
ISSN
2674-3000
Compartir este registro
Citación
Documentos PDF
Abstract
Introduction: The most frequent subtype of breast cancer is the luminal one, in 70 to 80% of cases; the poor response to neoadjuvant
hemotherapy of these tumors positions neoadjuvant hormone therapy as atreatment option.
Materials and Methods: An observational, descriptive, historical cohort study was conducted in patients with hormone receptor (HR positive and HER2-positive breast cancer, managed with neoadjuvant hormonetherapy in the INC (National Cancer Institute, for its initials in spanish), with the aim of evaluating theirclinical and pathological response.
Results: 57 patients were managed with neoadjuvant hormone therapy. Most stage IIA patients (40.3%, n = 23). 86% (n = 49) had luminal A tumors. Letrozole was the most widely used drug, in 78.9% (n = 45).
The overall response rate (ORR) was reached in 94.6% (n = 53); and 10.7% of the patients (n = 6) achieved complete clinical response (cCR). Complete pathological response (pCR) was achieved only in one patient. Conservative surgery was possible in 56.9% (n = 29) of the patients. There was no difference between the type of aromatase inhibitor (AI) and the duration of neoadjuvant hormonal treatment with the clinical response. With a median follow-up of 3 years (0.6 and 6 years), no disease progression was reported in any of the patients in the study.
Conclusion: The results of this study support the neoadjuvant hormone therapy recommendations for postmenopausal patients older than 65 years with luminal breast cancer, with well or moderately differentiated tumors, strongly HR positive and low Ki 67.
Enlace al recurso
https://www.sciencerepository.org/clinical-experience-with-the-use-of-neoadjuvant-hormone-therapy-for_JSO-2020-3-108Fuente
Journal of Surgical Oncology; Volumen 3 Número 3 , Páginas 1 - 6 (2020)
Estadísticas Google Analytics
Colecciones
- Artículos [246]